BR112022020203A2 - Composição de nanopartículas lipídicas - Google Patents
Composição de nanopartículas lipídicasInfo
- Publication number
- BR112022020203A2 BR112022020203A2 BR112022020203A BR112022020203A BR112022020203A2 BR 112022020203 A2 BR112022020203 A2 BR 112022020203A2 BR 112022020203 A BR112022020203 A BR 112022020203A BR 112022020203 A BR112022020203 A BR 112022020203A BR 112022020203 A2 BR112022020203 A2 BR 112022020203A2
- Authority
- BR
- Brazil
- Prior art keywords
- lipid nanoparticles
- composition
- lipids
- lipid
- prophylactic
- Prior art date
Links
- 150000002632 lipids Chemical group 0.000 title abstract 7
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/24—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/32—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and esterified hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/24—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/26—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/14—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/22—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
Abstract
COMPOSIÇÃO DE NANOPARTÍCULAS LIPÍDICAS. A presente invenção refere-se a lipídios que podem ser usados em combinação com outros componentes lipídicos, como lipídios neutros, colesterol e lipídios conjugados com polímero, para formar nanopartículas lipídicas para distribuição de agentes terapêuticos (por exemplo, moléculas de ácido nucleico) para fins terapêuticos ou profiláticos, incluindo vacinação.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010275664 | 2020-04-09 | ||
US202063011140P | 2020-04-16 | 2020-04-16 | |
CN202110299761 | 2021-03-19 | ||
PCT/CN2021/085879 WO2021204175A1 (en) | 2020-04-09 | 2021-04-08 | Lipid nanoparticle composition |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022020203A2 true BR112022020203A2 (pt) | 2022-11-22 |
Family
ID=75746092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022020203A BR112022020203A2 (pt) | 2020-04-09 | 2021-04-08 | Composição de nanopartículas lipídicas |
Country Status (13)
Country | Link |
---|---|
US (2) | US11472766B2 (pt) |
EP (1) | EP4077272A1 (pt) |
JP (1) | JP2023529522A (pt) |
KR (1) | KR20220166802A (pt) |
CN (2) | CN114206827B (pt) |
AU (1) | AU2021254312B2 (pt) |
BR (1) | BR112022020203A2 (pt) |
CA (1) | CA3178455A1 (pt) |
IL (1) | IL297084A (pt) |
MX (1) | MX2022012630A (pt) |
TW (1) | TW202204309A (pt) |
WO (1) | WO2021204175A1 (pt) |
ZA (1) | ZA202210782B (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
SI3718565T1 (sl) | 2015-10-22 | 2022-08-31 | Modernatx, Inc. | Cepiva za respiratorni virus |
MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
MA52262A (fr) | 2017-03-15 | 2020-02-19 | Modernatx Inc | Vaccin à large spectre contre le virus de la grippe |
WO2018170347A1 (en) | 2017-03-17 | 2018-09-20 | Modernatx, Inc. | Zoonotic disease rna vaccines |
EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
MX2022003269A (es) | 2019-09-19 | 2022-07-04 | Modernatx Inc | Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos. |
CA3214481A1 (en) * | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
WO2022204491A1 (en) * | 2021-03-26 | 2022-09-29 | Modernatx, Inc. | Pertussis vaccine |
AR127312A1 (es) | 2021-10-08 | 2024-01-10 | Suzhou Abogen Biosciences Co Ltd | Compuestos lipídicos ycomposiciones de nanopartículas lipídicas |
AU2022358824A1 (en) | 2021-10-08 | 2024-04-11 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
WO2023107400A1 (en) * | 2021-12-06 | 2023-06-15 | Ohio State Innovation Foundation | Diamino lipid (dal) compounds and pharmaceutical compositions comprising an immunotherapeutic agent |
CN116332830A (zh) * | 2021-12-23 | 2023-06-27 | 苏州艾博生物科技有限公司 | 脂质化合物和脂质纳米颗粒组合物 |
WO2023143600A1 (zh) * | 2022-01-30 | 2023-08-03 | 康希诺生物股份公司 | 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗 |
WO2023143591A1 (zh) * | 2022-01-30 | 2023-08-03 | 康希诺生物股份公司 | 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗 |
CN116514672A (zh) * | 2022-01-30 | 2023-08-01 | 康希诺生物股份公司 | 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗 |
KR102560772B1 (ko) * | 2022-03-21 | 2023-07-28 | 주식회사 메디치바이오 | 신규한 이온화지질 및 이를 이용한 지질나노입자 조성물 |
CN116924923A (zh) * | 2022-04-02 | 2023-10-24 | 科镁信(上海)生物医药科技有限公司 | 阳离子脂质、脂质体及用途 |
CN117417264A (zh) * | 2022-07-19 | 2024-01-19 | 深圳深信生物科技有限公司 | 氨基脂质化合物、其制备方法和应用 |
WO2024023174A2 (en) * | 2022-07-28 | 2024-02-01 | Aldexchem Kft. | Ionizable cationic lipids incorporating silicon |
WO2024037578A1 (en) | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
WO2024061204A1 (zh) * | 2022-09-19 | 2024-03-28 | 苏州盛迪亚生物医药有限公司 | 一种制备2-羟乙基氨基己酸酯类化合物方法及其应用 |
CN115947671B (zh) * | 2022-11-21 | 2023-09-26 | 荣灿生物医药技术(上海)有限公司 | 一种含氨基甲酸酯键的脂质化合物及其应用 |
CN116063205B (zh) * | 2023-01-04 | 2024-02-02 | 上海桢曜生物科技合伙企业(有限合伙) | 一种含烷基化氨基甲酸酯键的脂质化合物及其应用 |
CN115947672B (zh) * | 2023-01-04 | 2024-02-27 | 成都威斯津生物医药科技有限公司 | 用于递送药物的化合物、脂质体及药物载体 |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2588339B2 (ja) * | 1992-06-02 | 1997-03-05 | 花王株式会社 | 新規ジアミノジエステル及びその製造法 |
US7097854B2 (en) | 1996-09-12 | 2006-08-29 | Medigene Oncology Gmbh | Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds |
DE19637043A1 (de) * | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Neue Aminoalkoholderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel und Reagenzien |
WO1999024595A1 (en) | 1997-11-12 | 1999-05-20 | The Brigham And Women's Hospital, Inc. | The translation enhancer element of the human amyloid precursor protein gene |
US7468275B2 (en) | 2000-01-28 | 2008-12-23 | The Scripps Research Institute | Synthetic internal ribosome entry sites and methods of identifying same |
EP1259602A1 (en) | 2000-01-28 | 2002-11-27 | The Scripps Research Institute | Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same |
ES2340499T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
JP5225087B2 (ja) | 2005-08-24 | 2013-07-03 | ザ スクリプス リサーチ インスティチュート | 翻訳エンハンサーエレメント依存性のベクター系 |
DE102006007433A1 (de) | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure |
US8304529B2 (en) | 2006-07-28 | 2012-11-06 | Life Technologies Corporation | Dinucleotide MRNA cap analogs |
JP2010507361A (ja) | 2006-07-31 | 2010-03-11 | キュアバック ゲーエムベーハー | 具体的には免疫刺激剤/アジュバントとしての、一般式(I):GlXmGn、または一般式(II):ClXmCnで表される核酸 |
DE102006051516A1 (de) | 2006-10-31 | 2008-05-08 | Curevac Gmbh | (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins |
DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
WO2008127688A1 (en) | 2007-04-13 | 2008-10-23 | Hart Communication Foundation | Synchronizing timeslots in a wireless communication protocol |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
CA2904904A1 (en) | 2007-12-11 | 2009-06-18 | The Scripps Research Institute | Compositions and methods related to mrna translational enhancer elements |
SG188104A1 (en) | 2008-01-31 | 2013-03-28 | Curevac Gmbh | Nucleic acids comprising formula (nuglxmgnnv)a and derivatives thereof as an immunostimulating agents /adjuvants |
WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
WO2010088927A1 (en) | 2009-02-09 | 2010-08-12 | Curevac Gmbh | Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds |
EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
WO2011063233A1 (en) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
EP2387999A1 (en) | 2010-05-21 | 2011-11-23 | CureVac GmbH | Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof |
US20130230884A1 (en) | 2010-07-16 | 2013-09-05 | John Chaput | Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation |
BR112013002298A2 (pt) | 2010-07-30 | 2016-05-24 | Curevac Gmbh | complexação de ácidos nucleicos com componentes catiônicos reticulados com dissulfeto para transfecção e estimulação imunológica. |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
KR101648986B1 (ko) | 2010-11-17 | 2016-08-30 | 두산인프라코어 주식회사 | 윤활 특성이 향상된 슬라이딩 베어링 |
WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
US9011903B2 (en) | 2011-06-08 | 2015-04-21 | Nitto Denko Corporation | Cationic lipids for therapeutic agent delivery formulations |
WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
US9579338B2 (en) | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
WO2013086373A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
US9616449B2 (en) | 2012-02-13 | 2017-04-11 | Absolute Completion Technologies Inc. | Apparatus for treating a wellbore screen and method |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
CN104220599A (zh) | 2012-03-27 | 2014-12-17 | 库瑞瓦格有限责任公司 | 人工核酸分子 |
KR20140139101A (ko) | 2012-03-27 | 2014-12-04 | 큐어백 게엠바하 | 5''top utr을 포함하는 인공 핵산 분자 |
CA2859452C (en) | 2012-03-27 | 2021-12-21 | Curevac Gmbh | Artificial nucleic acid molecules for improved protein or peptide expression |
ES2719598T3 (es) | 2012-05-25 | 2019-07-11 | Curevac Ag | Inmovilización reversible y/o liberación controlada de ácidos nucleicos contenidos en nanopartículas mediante revestimientos poliméricos (biodegradables) |
WO2014028487A1 (en) * | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
SG10201710472PA (en) | 2013-02-22 | 2018-02-27 | Curevac Ag | Combination of vaccination and inhibition of the pd-1 pathway |
WO2015002667A1 (en) | 2013-07-01 | 2015-01-08 | Myq, Inc. | A location regulated point-of-sale system and enhancements |
WO2015011633A1 (en) | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
RU2733424C2 (ru) | 2013-08-21 | 2020-10-01 | Куревак Аг | Способ повышения экспрессии кодируемых рнк белков |
CN110195072A (zh) | 2013-08-21 | 2019-09-03 | 库瑞瓦格股份公司 | 狂犬病疫苗 |
KR20160042935A (ko) | 2013-08-21 | 2016-04-20 | 큐어백 아게 | 폐암 치료를 위한 조성물 및 백신 |
CN105517566A (zh) | 2013-08-21 | 2016-04-20 | 库瑞瓦格股份公司 | 用于治疗前列腺癌的组合物和疫苗 |
WO2015024669A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Combination vaccine |
RU2723328C2 (ru) | 2013-08-21 | 2020-06-09 | Куревак Аг | Вакцина против респираторно-синцитиального вируса (рсв) |
ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
AU2014348212C1 (en) | 2013-11-18 | 2018-11-29 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
CA2927862C (en) | 2013-12-30 | 2024-01-23 | Curevac Ag | Artificial nucleic acid molecules |
SG10201805660WA (en) | 2013-12-30 | 2018-08-30 | Curevac Ag | Methods for rna analysis |
JP6584414B2 (ja) | 2013-12-30 | 2019-10-02 | キュアバック アーゲー | 人工核酸分子 |
PL3766916T3 (pl) | 2014-06-25 | 2023-02-27 | Acuitas Therapeutics Inc. | Nowe lipidy i formulacje nanocząstek lipidowych do dostarczania kwasów nukleinowych |
US20180303925A1 (en) | 2015-04-27 | 2018-10-25 | The Trustees Of The University Of Pennsylvania | Nucleoside-Modified RNA For Inducing an Adaptive Immune Response |
WO2016210190A1 (en) * | 2015-06-24 | 2016-12-29 | Nitto Denko Corporation | Ionizable compounds and compositions and uses thereof |
US10221127B2 (en) | 2015-06-29 | 2019-03-05 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
AU2016324310B2 (en) | 2015-09-17 | 2021-04-08 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
AU2016369612B2 (en) | 2015-12-17 | 2023-06-01 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-CoA mutase |
JP7114465B2 (ja) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | 薬剤の細胞内送達のための化合物および組成物 |
WO2017180917A2 (en) | 2016-04-13 | 2017-10-19 | Modernatx, Inc. | Lipid compositions and their uses for intratumoral polynucleotide delivery |
WO2017201317A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polyribonucleotides containing reduced uracil content and uses thereof |
WO2017201333A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia |
JP7194594B2 (ja) | 2016-05-18 | 2022-12-22 | モデルナティエックス インコーポレイテッド | 免疫調節ポリペプチドをコードするmRNAの組み合わせ及びその使用 |
US11001861B2 (en) | 2016-05-18 | 2021-05-11 | Modernatx, Inc. | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 |
US20200085916A1 (en) | 2016-05-18 | 2020-03-19 | Modernatx, Inc. | Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria |
WO2017201349A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 |
EP3458104A1 (en) | 2016-05-18 | 2019-03-27 | Modernatx, Inc. | Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria |
WO2017201328A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE |
EP3458108A4 (en) | 2016-05-18 | 2020-04-22 | ModernaTX, Inc. | POLYNUCLEOTIDES FOR CODING THE TRANSMEMBRANE CONDUCTIVE REGULATOR OF CYSTIC FIBROSE FOR TREATING CYSTIC FIBROSE |
DK3458083T3 (da) | 2016-05-18 | 2023-01-30 | Modernatx Inc | Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf |
US20190275170A1 (en) | 2016-05-18 | 2019-09-12 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
SG11201903460QA (en) | 2016-10-26 | 2019-05-30 | Curevac Ag | Lipid nanoparticle mrna vaccines |
DK3538515T3 (da) | 2016-11-08 | 2022-10-17 | Univ Ramot | Kationiske lipider til nukleinsyreafgivelse og fremstilling deraf |
US20180185516A1 (en) | 2016-12-09 | 2018-07-05 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
US10526284B2 (en) | 2016-12-21 | 2020-01-07 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
MA47787A (fr) | 2017-03-15 | 2020-01-22 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
MA52262A (fr) | 2017-03-15 | 2020-02-19 | Modernatx Inc | Vaccin à large spectre contre le virus de la grippe |
WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
AU2018234692B2 (en) * | 2017-03-15 | 2022-06-02 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
JP7297676B2 (ja) * | 2017-04-28 | 2023-06-26 | アクイタス セラピューティクス インコーポレイテッド | 新規なカルボニル脂質、および核酸を送達するための脂質ナノ粒子製剤 |
US20200131498A1 (en) | 2017-06-14 | 2020-04-30 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
US11639329B2 (en) | 2017-08-16 | 2023-05-02 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
CA3073018A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
WO2019089828A1 (en) | 2017-10-31 | 2019-05-09 | Acuitas Therapeutics, Inc. | Lamellar lipid nanoparticles |
EP4331681A2 (en) * | 2018-08-21 | 2024-03-06 | Kabushiki Kaisha Toshiba | Method for delivering activators to cells |
JP7410135B2 (ja) * | 2018-09-19 | 2024-01-09 | モデルナティエックス インコーポレイテッド | 治療薬の細胞内送達のための化合物及び組成物 |
EP3908568A1 (en) | 2019-01-11 | 2021-11-17 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
-
2021
- 2021-04-08 EP EP21722369.2A patent/EP4077272A1/en active Pending
- 2021-04-08 WO PCT/CN2021/085879 patent/WO2021204175A1/en unknown
- 2021-04-08 MX MX2022012630A patent/MX2022012630A/es unknown
- 2021-04-08 AU AU2021254312A patent/AU2021254312B2/en active Active
- 2021-04-08 TW TW110112766A patent/TW202204309A/zh unknown
- 2021-04-08 JP JP2022560342A patent/JP2023529522A/ja active Pending
- 2021-04-08 BR BR112022020203A patent/BR112022020203A2/pt unknown
- 2021-04-08 CN CN202180004363.0A patent/CN114206827B/zh active Active
- 2021-04-08 CN CN202310829589.5A patent/CN117003658A/zh active Pending
- 2021-04-08 CA CA3178455A patent/CA3178455A1/en active Pending
- 2021-04-08 IL IL297084A patent/IL297084A/en unknown
- 2021-04-08 KR KR1020227034931A patent/KR20220166802A/ko unknown
-
2022
- 2022-01-27 US US17/586,488 patent/US11472766B2/en active Active
- 2022-08-23 US US17/821,738 patent/US20230286902A1/en active Pending
- 2022-09-29 ZA ZA2022/10782A patent/ZA202210782B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP4077272A1 (en) | 2022-10-26 |
AU2021254312A1 (en) | 2022-10-27 |
MX2022012630A (es) | 2022-11-07 |
IL297084A (en) | 2022-12-01 |
US20230286902A1 (en) | 2023-09-14 |
TW202204309A (zh) | 2022-02-01 |
JP2023529522A (ja) | 2023-07-11 |
KR20220166802A (ko) | 2022-12-19 |
AU2021254312B2 (en) | 2024-01-11 |
CN117003658A (zh) | 2023-11-07 |
US20220153686A1 (en) | 2022-05-19 |
ZA202210782B (en) | 2023-04-26 |
US11472766B2 (en) | 2022-10-18 |
CN114206827B (zh) | 2023-05-23 |
CA3178455A1 (en) | 2021-10-14 |
CN114206827A (zh) | 2022-03-18 |
WO2021204175A1 (en) | 2021-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022020203A2 (pt) | Composição de nanopartículas lipídicas | |
MX2019005287A (es) | Lipidos cationicos para suministro de acido nucleico y su preparacion. | |
BR112022001192A2 (pt) | Composições estáveis de nanopartículas lipídicas carregadas com mrna e processos de produção | |
WO2022152109A3 (en) | Lipid compounds and lipid nanoparticle compositions | |
BRPI0900496A2 (pt) | processo de inversão de fases isento de solventes para produzir emulsões de resinas | |
BR112013023757A2 (pt) | método para redução de viscosidade no processo de sacarificação | |
BR112016006122A2 (pt) | composições imunogênicas e métodos com coronavírus da síndrome respiratória do oriente médio (mers-cov) | |
ZA202305909B (en) | Lipid compounds and lipid nanoparticle compositions | |
BR112014014804A2 (pt) | composição para o tingimento por oxidação de fibras de queratina, compreendendo álcoois graxos particulares, uma substância graxa líquida e um polímero catiônico | |
BR112015010059A2 (pt) | terapia adjuvante com inibidor da quinase da família tec | |
BR112015018416A2 (pt) | fórmulas à base de proteína hidrolisada e aminoácidos com um sistema de emulsão estável | |
BR112014003099A2 (pt) | grampo cirúrgico com revestimento auxiliar localizado | |
BR112016022499A2 (pt) | Produtos terapêuticos combinatórios supramoleculares | |
BR112015002372A2 (pt) | composições e métodos para a redução do teor de álcool no sangue | |
BR112015016466A2 (pt) | método para o tratamento de câncer baseado no estado de mutação de k-ras | |
BR112014004687A2 (pt) | imidazopiridazinas amino-substituídas | |
BR112015022819A2 (pt) | formulações modificadas de lipossoma de docetaxel | |
BR112015000174A2 (pt) | método para o tratamento da artrite | |
BR112013020167A2 (pt) | melhoradores de permeação para formulações tópicas | |
BR112015020990A2 (pt) | imidazopiridazinas substituídas | |
BR112014013876A2 (pt) | vacina à base de toxina de clostridium difficile | |
BR112016001919A2 (pt) | composição cosmética e processo de tratamento cosmético | |
BR112013021661A2 (pt) | objetivação de fator de coagulação a tlt-1 sobre plaquetas ativadas | |
BR112018000242A2 (pt) | composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico | |
WO2022152141A3 (en) | Polymer conjugated lipid compounds and lipid nanoparticle compositions |